Open AccessJournal Article
Cancer of the esophagus
T Watamuki,T Fumoto,I Tamaki +2 more
Reads0
Chats0
About:
This article is published in Geka chiryo. Surgical therapy.The article was published on 1970-07-01 and is currently open access. It has received 164 citations till now. The article focuses on the topics: Cancer & Esophagus.read more
Citations
More filters
Journal ArticleDOI
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
Anne-Marie Mandard,Frédéric Dalibard,Jean-Claude Mandard,Jacques Marnay,Michel Henry-Amar,Jean-François Petiot,Alain Roussel,Jacques-Henry Jacob,Philippe Segol,Guy Samama,Jean-Marie Ollivier,Sylvie Bonvalot,M. Gignoux +12 more
TL;DR: A pilot study was undertaken to determine if pathologic assessment of tumor regression correlated with disease free survival in patients with esophageal carcinoma.
Journal ArticleDOI
Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world.
J. R. Siewert,Hubert J. Stein,Marcus Feith,Bjorn L. D. M. Bruecher,Holger Bartels,Ulrich Fink +5 more
TL;DR: Esophagectomy for esophageal cancer has become a safe procedure in experienced hands and has a better long-term prognosis after resection than squamous cell carcinoma.
Journal ArticleDOI
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
John M. Inadomi,Richard E. Sampliner,Jesper Lagergren,David A. Lieberman,A. Mark Fendrick,Nimish Vakil +5 more
TL;DR: Decision analysis was used to determine whether current recommendations for screening of patients with gastroesophageal reflux disease (GERD) represent cost-effective care and to identify clinical variables critical to the determination of cost-effectiveness.
Journal ArticleDOI
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Juan W. Valle,Anne C Armstrong,Chris Newman,Valery Yu Alakhov,Grzegorz Pietrzynski,Julie Brewer,Sue Campbell,Pippa Corrie,Eric K. Rowinsky,Malcolm R Ranson +9 more
TL;DR: SP1049C has a notable single-agent activity in patients with adenocarcinoma of the esophagus and GEJ, as well as an acceptable safety profile, and the results of preclinical studies demonstrating superior antitumor activity of SP10 49C compared with doxorubicin in a standard formulation indicate that further evaluations of SP 1049C alone or combined with other relevant therapeutics in this disease setting are warranted.
Journal ArticleDOI
Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival
James M. Donahue,Francis C. Nichols,Zhuo Li,David A. Schomas,Mark S. Allen,Stephen D. Cassivi,Aminah Jatoi,Robert C. Miller,Dennis A. Wigle,K. Robert Shen,Claude Deschamps +10 more
TL;DR: Patients with complete pathologic response have significantly improved long-term survival compared with patients with near complete and partial responses and future efforts should be directed at understanding determinants of complete responses.
References
More filters
Journal ArticleDOI
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
Anne-Marie Mandard,Frédéric Dalibard,Jean-Claude Mandard,Jacques Marnay,Michel Henry-Amar,Jean-François Petiot,Alain Roussel,Jacques-Henry Jacob,Philippe Segol,Guy Samama,Jean-Marie Ollivier,Sylvie Bonvalot,M. Gignoux +12 more
TL;DR: A pilot study was undertaken to determine if pathologic assessment of tumor regression correlated with disease free survival in patients with esophageal carcinoma.
Journal ArticleDOI
Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world.
J. R. Siewert,Hubert J. Stein,Marcus Feith,Bjorn L. D. M. Bruecher,Holger Bartels,Ulrich Fink +5 more
TL;DR: Esophagectomy for esophageal cancer has become a safe procedure in experienced hands and has a better long-term prognosis after resection than squamous cell carcinoma.
Journal ArticleDOI
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
John M. Inadomi,Richard E. Sampliner,Jesper Lagergren,David A. Lieberman,A. Mark Fendrick,Nimish Vakil +5 more
TL;DR: Decision analysis was used to determine whether current recommendations for screening of patients with gastroesophageal reflux disease (GERD) represent cost-effective care and to identify clinical variables critical to the determination of cost-effectiveness.
Journal ArticleDOI
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Juan W. Valle,Anne C Armstrong,Chris Newman,Valery Yu Alakhov,Grzegorz Pietrzynski,Julie Brewer,Sue Campbell,Pippa Corrie,Eric K. Rowinsky,Malcolm R Ranson +9 more
TL;DR: SP1049C has a notable single-agent activity in patients with adenocarcinoma of the esophagus and GEJ, as well as an acceptable safety profile, and the results of preclinical studies demonstrating superior antitumor activity of SP10 49C compared with doxorubicin in a standard formulation indicate that further evaluations of SP 1049C alone or combined with other relevant therapeutics in this disease setting are warranted.
Journal ArticleDOI
Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival
James M. Donahue,Francis C. Nichols,Zhuo Li,David A. Schomas,Mark S. Allen,Stephen D. Cassivi,Aminah Jatoi,Robert C. Miller,Dennis A. Wigle,K. Robert Shen,Claude Deschamps +10 more
TL;DR: Patients with complete pathologic response have significantly improved long-term survival compared with patients with near complete and partial responses and future efforts should be directed at understanding determinants of complete responses.